GlassScriptPhysician profile
Ulrich O Ringwald
NPI 1700876364
$6,210.86
in general payments reported to CMS, 2019-2025
20 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $656 · 2021: $718 · 2022: $1,067 · 2023: $1,000 · 2024: $1,055 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,047 · Education: $47.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,046.52 |
| Education | $47.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,413.22 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $801.98 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $676.10 | 2019-2025 | Dupixent |
| Genzyme Corporation | $629.17 | 2019-2025 | |
| Genentech USA, INC. | $518.04 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.90 | 2019-2023 | Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $357.88 | 2019-2025 | |
| Csl Behring | $309.62 | 2019-2025 | Haegarda, Andembry |
| Teva Pharmaceuticals USA, INC. | $252.76 | 2020-2022 | |
| Amgen INC. | $216.23 | 2021-2025 | Tezspire |
| Optinose US, INC. | $106.82 | 2019-2022 | |
| Covis Pharma Gmbh | $78.65 | 2021-2023 | |
| Abbvie INC. | $74.41 | 2022-2023 | Ubrelvy |
| Kaleo, INC. | $70.41 | 2019-2022 | |
| Aytu Biopharma, INC. | $61.33 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $53.54 | 2025 | Neffy |
| Tersera Therapeutics LLC | $38.11 | 2023 | Quzyttir |
| Alk-Abello, INC | $34.00 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $30.67 | 2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $16.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulrich Ringwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.